Overexpression of MMP-1 and VEGF-C is associated with a less favorable prognosis in esophageal squamous cell carcinoma

Onkologie

Volumn 35, Issue 11, 2012, Pages 651-656

  Tao, Yi Sheng ^a,b   Ma, Xin Yi ^c   Chai, Da Min ^b   Ma, Li ^b   Feng, Zhen Zhong ^b   Cheng, Ze Nong ^b   Lai, Mao De ^a  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b BENGBU MEDICAL COLLEGE   (China)

^c Limited Company of Medicine Inspection Center   (China)

Author keywords

Esophagus; Matrix metalloproteinase 1; Prognosis; Squamous cell carcinoma; Vascular endothelial growth factor C

Indexed keywords

COMPLEMENTARY DNA; INTERSTITIAL COLLAGENASE; MESSENGER RNA; VASCULOTROPIN C;

ARTICLE; CANCER INVASION; CANCER PROGNOSIS; CANCER SIZE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGUS HYPERPLASIA; ESOPHAGUS RESECTION; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MICROARRAY ANALYSIS; OVERALL SURVIVAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION;

CARCINOMA, SQUAMOUS CELL; CHINA; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; INCIDENCE; MALE; MATRIX METALLOPROTEINASE 1; PROGNOSIS; RISK ASSESSMENT; SURVIVAL ANALYSIS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION; VASCULAR ENDOTHELIAL GROWTH FACTOR C;

EID: 84870004939     PISSN: 0378584X     EISSN: 14230240     Source Type: Journal    
DOI: 10.1159/000343637     Document Type: Article

References (30)

1. Enzinger PC, Mayer RJ: Esophageal cancer. N Engl J Med 2003;349:2241-2252.
2. Mariette C, Balon JM, Piessen G, Fabre S, Van Seuningen I, Triboulet JP: Pattern of recurrence following complete resection of esophageal carcinoma and factors predictive of recurrent disease. Cancer 2003;97:1616-1623.
3. Hanahan D, Weinberg RA: The hallmarks of cancer. Cell 2000;100:57-70.
4. Morales CP, Souza RF, Spechler SJ: Hallmarks of cancer progression in Barrett's oesophagus. Lancet 2002;360:1587-1589.
5. Murray GI, Duncan ME, O'Neil P, McKay JA, Melvin WT, Fothergill JE: Matrix metalloproteinase- 1 is associated with poor prognosis in oesophageal cancer. J Pathol 1998;185:256-261.
6. Tanioka Y, Yoshida T, Yagawa T, Saiki Y, Takeo S, Harada T, Okazawa T,Yanai H, Okita K: Matrix metalloproteinase-7 and matrix metalloproteinase- 9 are associated with unfavourable prognosis in superficial oesophageal cancer. Br J Cancer 2003;89:2116-2121.
7. Wang FQ, Fisher J, Fishman DA: MMP-1-PAR1 axis mediates LPA-induced epithelial ovarian cancer (EOC) invasion. Gynecol Oncol 2011;120:247- 255.
8. Amos S, Redpath GT, Dipierro CG, Carpenter JE, Hussaini IM: Epidermal growth factor receptormediated regulation of urokinase plasminogen activator expression and glioblastoma invasion via C-SRC/MAPK/AP-1 signaling pathways. J Neuropathol Exp Neurol 2010;69:582-592.
9. Takahashi S, Yamada-Okabe H, Hamada K, Ohta S, Kawase T, Yoshida K, Toda M: Downregulation of uPARAP mediates cytoskeletal rearrangements and decreases invasion and migration properties in glioma cells. J Neurooncol 2011;103:267-276.
10. Murray GI, Duncan ME, O'Neil P, et a1.: Matrix metalloproteinase-1 is associated with poor prognosis in oesophageal cancer. J Pathol 1998;185:256- 261.
11. Iwasaka C, Tanaka K, Abe M, Sato Y: Ets-1 regulates angiogenesis by inducing the expression of urokinase-type plasminogen activator and matrix metalloproteinase-1 and the migration of vascular endothelial cells. J Cell Physiol 1996;169:522-531.
12. Ferrara N, Davis-Smyth T: The biology of vascular endothelial growth factor. Endocr Rev 1997;18:4- 25.
13. Jenny B, Harrison JA, Baetens D, Tille JC, Burkhardt K, Mottaz H, et al.: Expression and localization of VEGF-C and VEGFR-3 in glioblastomas and haemangioblastomas. J Pathol 2006;209: 34-43.
14. Witte D, Thomas A, Ali N, Carlson N, Younes M: Expression of the vascular endothelial growth factor receptor-3 (VEGFR-3)and its ligand VEGF-C in human colorectal adenocarcinoma. Anticancer Res 2002;22:1463-1466.
15. Li R, Younes M, Wheeler TM, Scardino P, Ohori M, Frolov A, et al.: Expression of vascular endothelial growth factor receptor-3 (VEGFR-3)in human prostate. Prostate 2004;58:193-199.
16. Juttner S, Wissmann C, Jons T, Vieth M, Hertel J, Gretschel S, Schlag PM, Kemmner W, Hocker M: Vascular endothelial growth factor-D and its receptor VEGFR-3:two novel independent prognostic markers in gastric adenocarcinoma. J Clin Oncol 2006;24:228-240.
17. Van Trappen PO, Steele D, Lowe DG, Baithun S, Beasley N, Thiele W, Weich H, Krishnan J, Shepherd JH, Pepper MS, Jackson DG, Sleeman JP, Jacobs IJ: Expression of vascular endothelial growth factor (VEGF)-C and VEGFD, and their receptor VEGFR-3,during different stages of cervical carcinogenesis. J Pathol 2003; 201:544-554.
18. Witte D, Thomas A, Ali N, Carlson N, Younes M: Expression of the vascular endothelial growth factor receptor-3 (VEGFR-3)and its ligand VEGF-C in human colorectal adenocarcinoma. Anticancer Res 2002;22:1463-1466.
19. Neuchrist C, Erovic BM, Handisurya A, Fischer MB, Steiner GE, Hollemann D, Gedlicka C, Saaristo A, Burian M: Vascular endothelial growth factor C and vascular endothelial growth factor receptor 3 expression in squamous cell carcinomas of the head and neck. Head Neck 2003;25:464-474.
20. Lee CH, Liu SY, Lin MH, Chiang WF, Chen TC, Huang WT, Chou DS, Chiu CT, Liu YC: Upregulation of matrix metalloproteinase-1 (MMP-1) expression in oral carcinomas of betel quid (BQ) users: roles of BQ ingredients in the acceleration of tumour cell motility through MMP-1. Arch Oral Biol 2008;53:810-818.
21. Yamashita K, Mori M, Kataoka A, Inoue H, Sugimachi K: The clinical significance of MMP-1 expression in oesophageal carcinoma. Br J Cancer 2001;84:276-282.
22. Murray GI, Duncan ME, O'Neil P, McKay JA, Melvin WT, Fothergill JE: Matrix metalloproteinase- 1 is associated with poor prognosis in oesophageal cancer. J Pathol 1998;185:256-261.
23. Sunami E, Tsuno N, Osada T, Saito S, Kitayama J, Tomozawa S, Tsuruo T,Shibata Y, Muto T, Nagawa H: MMP-1 is a prognostic marker for hematogenous metastasis of colorectal cancer. Oncologist 2000;5:108-114.
24. Vizoso FJ, Gonzalez LO, Corte MD, Rodriguez JC, Vazquez J, Lamelas ML,Junquera S, Merino AM, Garcia-Muniz JL: Study of matrix metalloproteinases and their inhibitors in breast cancer. Br J Cancer 2007;96:903-911.
25. Wang F, Wei L, Chen L: The relationship between vascular endothelial growth factor, microvascular density, lymph node metastasis and prognosis of breast carcinoma. Zhonghua Binglixue Zazhi 2000; 29:172-175.
26. Adams J, Carder PJ, Downey S, Forbes MA, MacLennan K, Allgar V, Kaufman S, Hallam S, Bicknell R, Walker JJ, Cairnduff F, Selby PJ, Perren TJ, Lansdown M, Banks RE: Vascular endothelial growth factor (VEGF) in breast cancer: comparison of plasma, serum, and tissue VEGF and microvessel density and effects of tamoxifen. Cancer Res 2000;60:2898-2905.
27. Zhang H, Yin Y, Zhang L, Zheng X, Gao D, Chen K, Zhang Y: The effects of vascular r endothelial growth factor C knockdown in esophageal squamous cell carcinoma. J Cancer Res Clin Oncol 2012;138:133-139.
28. Kozlowski M, Naumnik W, Niklinski J, Milewski R, Dziegielewski P, Laudanski J: Vascular endothelial growth factor C and D expression correlates with lymph node metastasis and poor prognosis in patients with resected esophageal cancer. Neoplasma 2011;58:311-319.
29. Tanaka T, Ishiguro H, Kuwabara Y, Kimura M, Mitsui A, Katada T, Shiozaki M, Naganawa Y, Fujii Y, Takeyama H: Vascular endothelial growth factor C (VEGF-C) in esophageal cancer correlates with lymph node metastasis and poor patient prognosis. J Exp Clin Cancer Res 2010;29:83.
30. Liu P, Zhou J, Zhu H, Xie L, Wang F, Liu B, Shen W, Ye W, Xiang B, Zhu X, Shi R, Zhang S: VEGF-C promotes the development of esophageal cancer via regulating CNTN-1 expression. Cytokine 2011;55:8-17.